Leukemia risk models in primary myelofibrosis: an International Working Group study Leukemia (2012) 26, 1439 --1441; doi:10.1038/leu.2011.374; published online 13 January 2012 Overall survival in primary myelofibrosis (PMF) is assessed by the International Prognostic Scoring System (IPSS), 1 at time of diagnosis, or the dynamic IPSS (DIPSS) 2 or DIPSS-plus, 3 at any time during the disease course, in the absence and presence of cytogenetic information, respectively. DIPSS-plus is based on eight risk factors: age465 years, constitutional symptoms, hemoglobin o10 g/dl, transfusion need, leukocyte count 425 Â 10 9 /l, platelet count o100 Â 10 9 /l, circulating blasts X1% and unfavorable karyotype. The latter includes complex karyotype or any one or two abnormalities that include þ 8, À7/7q-, i(17q), À5/5q-, 12p-, inv(3) or 11q23 rearrangement. 4 In regards to leukemia-free survival (LFS), recent studies have highlighted the prognostic significance of monosomal karyotype (MK), 5 unfavorable karyotype, 3, 4, 6 circulating blasts X3%, 7 platelet count o100 Â 10 9 /l, 3, 7 transfusion need 8, 9 and DIPSS. 10 Similarly, patients with PMF or post-polycythemia vera/essential thrombocythemia myelofibrosis face a higher risk of death and leukemic transformation (LT) in the presence of chromosome 17 abnormalities, circulating blasts X10% or platelets o50 Â 10 9 /l. 11 In the current study, multivariable and receiver operating characteristic (ROC) analyses were applied to an institutional database of 884 karyotypically annotated patients with PMF, in order to define karyotypedependent and karyotype-independent risk models for LFS. A separate cohort of 525 patients from an international database 2 was used to validate the karyotype-independent model. The diagnoses of PMF and LT were according to the World Health Organization criteria. 12 All statistical analyses considered clinical and laboratory parameters obtained at the time of referral to the Mayo Clinic. Variables considered in patients from the international database were those obtained at the time of initial diagnosis. ROC plots were prepared to determine the best discriminant levels for continuous variables in predicting LT. The end point used in this regard (that is, the binary outcome) was the occurrence or nonoccurrence of LT at 5 years after diagnosis. 13 In other words, patients were classified as alive and leukemia-free/censored when follow-up time was 45 years and as leukemia/uncensored for patients known to have transformed into acute leukemia before this time point. The performance of the selected cut-off values was quantified by the area under the ROC curve (AUC). LFS was calculated from the date of first referral to date of LT (uncensored) or death/last contact (censored). LFS survival curves were prepared by the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazard regression model was used for multivariable analysis. P-values o0.05 were considered significant. The Stat View (SAS Institute, Cary, NC, USA) and JMP (SAS Institute) statistical packages were used for all computations.
The current study included 884 patients with PMF seen at the Mayo Clinic between 1977 and 2011. In this Mayo cohort, 517 patients were seen within the first year of their diagnosis. JAK2V617F, MPL and IDH mutation status was available in 514, 338 and 305 patients, respectively. The corresponding mutational frequencies were 60%, 8% and 4%. To date, 564 (64%) deaths have been recorded and median follow-up of living patients was 36 months (range, 0.1 --296). There were a total of 60 documented cases of LTs. Treatment was according to the treating physician's discretion and included observation alone, conventional drugs, involved field irradiation, splenectomy (n ¼ 164; 19%) and allogeneic stem cell transplantation (n ¼ 33; 4%).
Clinical and laboratory parameters obtained at time of referral to the Mayo Clinic were systematically examined for their value in predicting LT. These parameters included currently acknowledged risk factors for overall survival in PMF. 3 In addition, on the basis of recent relevant information, MK 5 and inv(3)/i(17q) abnormalities 11 were considered separately from other unfavorable karyotype.
A 5-year LT ROC plots were constructed for circulating blast, leukocyte and platelet counts. The respective AUC for the ROC plots were 0.70, 0.71 and 0.55. Accordingly, we proceeded further in determining the best cut-off levels for increased circulating blast percentage and thrombocytopenia, which were 2% and 41 Â 10 9 /l, respectively (ROC plots using 3 instead of 5 years as the end point yielded similar results). These two cut-off levels were subsequently used in multivariable analyses that included the DIPSS-plus risk factors including age 465 years, hemoglobin o10 g/dl, leukocyte count 425 Â 10 9 /l, presence of constitutional symptoms, transfusion need and unfavorable karyotype. 3 As mentioned above, unfavorable karyotype was treated as three separate subcategories: MK, inv(3)/i(17q) abnormalities and other unfavorable karyotype.
On multivariable analysis, the following were identified as independent predictors of inferior LFS: MK (Hazard ratio (HR) 6.2, 95% confidence intervals (CI) 2.2 --17.1; P ¼ 0.0004), inv(3)/i(17q) abnormalities (HR 7.6, 95% CI 1.8--33.3; P ¼ 0.007), circulating blasts X2% (HR 2.4, 95% CI 1.4--4.2; P ¼ 0.002) and platelet count p41 Â 10 9 /l (HR 2.6, 95% CI 1.3--5.1; P ¼ 0.008). MK and inv(3)/ i(17q) abnormalities were subsequently consolidated into one very high risk cytogenetic category (n ¼ 27), with a corresponding HR of 6.6 (95% CI 2.7 --16.0). HR-based risk scores were assigned to very high risk karyotype (2 points), circulating blasts X2% (1 point) and platelet count p50 Â 10 9 /l (1 point) to classify patients into low (no adverse points; n ¼ 522), intermediate (1 adverse point; n ¼ 290) and high risk (X2 adverse points; n ¼ 72) groups; the corresponding 3-year LT rates were 3%, 10% (HR 2.6; 95% CI 1.4 --4.6; P ¼ 0.002) and 35% (HR 9.4, 95% CI 4.7 --18.7; Po0.0001) (Figure 1) . None of the other covariates, including age 465 years, hemoglobin o10 g/dl, leukocyte count 425 Â 10 9 /l, presence of constitutional symptoms, transfusion need or unfavorable karyotype other than MK or inv(3)/i(17q) abnormalities were independently significant (P40.1 in all instances).
The karyotype-independent model was developed using the aforementioned cut-off values for circulating blast percentage (X2%; 1 adverse point) and platelet count (p50 Â 10 9 /l; 1 adverse point); low-risk (no adverse points; n ¼ 525), intermediate-risk Figure 1 . LFS data of 884 Mayo Clinic patients with PMF stratified by a karyotype-dependent risk model. Risk scores were assigned to very high risk karyotype (2 points), peripheral blood blast X2% (1 point) and platelet count p50 Â 10 9 /l (1 point) to classify patients into low (no adverse points; n ¼ 522), intermediate (1 adverse point; n ¼ 290) and high risk (X2 adverse points; n ¼ 72) groups. Very high risk karyotype included MK, inv (3) or i(17q) abnormalities.
(1 adverse point; n ¼ 311) and high-risk (2 adverse points; n ¼ 48); the corresponding 3-year LT rates were 3%, 12% (HR 3.1, 95% CI 1.8 --5.4; Po0.0001) and 25% (HR 6.0, 95% CI 2.6 --14.1; Po0.0001) (Supplementary Figure 1) . None of the other covariates, including age 465 years, hemoglobin o10 g/dl, leukocyte count 425 Â 10 9 /l, presence of constitutional symptoms or red cell transfusion need were independently significant (P40.1 in all instances). The karyotype-independent model was validated in a separate cohort of 525 PMF patients from an international database,(10) using variables obtained at time of initial diagnosis (Supplementary Table 1 ; Supplementary Figure 2) .
Accurate disease prognostication in PMF is crucial for the selection of patients in whom the risk associated with allogeneic stem cell transplantation or participation in new drug trials is justified. Moreover, the therapeutic implications of impending LT are different from those of progressive disease characterized by bone marrow failure and marked hepatosplenomegaly. In other words, the need for allogeneic stem cell transplantation might be more urgent in the presence of risk factors for LT whereas, in their absence, it is reasonable to pursue investigational drug therapy that targets specific disease complications, such as anemia or splenomegaly.
14 We have previously reported that patients with DIPSS high (HR 24.9) and intermediate-2 (7.8) risk disease were more likely to undergo LT, compared with patients with low-risk disease. 10 However, a more recent analysis suggested that some but not all components of DIPSS or DIPSS-plus were independently predictive of LT, and that the separate consideration of certain risk factors neutralized the aggregate association between DIPSS/DIPSS-plus and LT. 3 Among the risk factors currently listed under IPSS/DIPSS/DIPSSplus, unfavorable karyotype, 3, 4, 6 platelet count o100 Â 10 9 /l 3,7 and red blood cell transfusion need 8, 9 have been independently associated with LT. In addition, recent studies have suggested additional value for MK, 5 /l and leukocyte count 430 Â 10 9 /l. 15 The current study, representing the largest karyotypically annotated study population in PMF (n ¼ 884), examined the prognostic contribution of each one of the aforementioned risk factors to come up with both karyotypedependent (preferable if available) and karyotype-independent risk models that are applicable at diagnosis or at the time of referral. The study revealed that the detrimental effect of unfavorable karyotype was mostly attributed to MK or inv(3)/i(17q) and that LT prediction was enhanced by using different cut-off values for circulating blasts and platelet counts. The current LT risk models complement DIPSSplus in the comprehensive prognostication of patients with PMF. At the same time, it is underscored that additional studies with better documentation of causes of death and implementation of statistical methods that account for competing risk of death are needed to validate and possibly improve upon the current risk models.
